(1 - 4 von 5
)
Study shows trabedersen as beneficial therapy of high-grade gliomas -...
ecancer.org
Results of a Phase IIb study, presented at the American Association for Cancer Research 101st Annual Meeting 2010, showed a clear clinical benefit from trabeder
TGF-beta2 inhibitor has clinical benefit in high-grade gliomas
www.healio.com
AACR st Annual Meeting
WASHINGTON, D.C. — The use of trabedersen, a TGF-beta2 specific
phosphorothioate antisense oligonucleotide, in patients...
Join: GEN Drug Discovery Theatre at BIOTECHNICA 2010
www.b3cnewswire.com
Dr. Piotr Jachimczak, physician and senior scientific advisor at Antisense Pharma, Regensburg. Therapies targeting TGF- β – an overview . PD Dr. Peter Hau, section leader
sortiert nach Relevanz / Datum